About
Dear Distinguished Life Science Leaders:
On behalf of American Conference Institute, we look forward to welcoming you to Financing Solutions and Strategies for Life Sciences in New York this October. With many companies facing a funding crisis, the need for an expert forum on finding solutions to the credit gap and bringing together investors and corporate stakeholders to explore different financial models has never been greater.
With the ways deals are being structured constantly changing, Financing Solutions and Strategies for Life Sciences stands apart as the one event where cutting-edge strategies will be exchanged and potential new relationships will be forged. With distinguished industry speakers and investors coming from notable investment groups including Silicon Valley Bank, OrbiMed, Takeda Research Investment, RBC Capital Markets, Atlas Venture and Paul Capital Healthcare, no other event will arm you both with the knowledge and the networking needed to secure successful financing.
With new stock offerings often no longer a viable option, both companies and venture investors are being forced to adapt. New financial strategies are emerging, and some less dilutive financing models are proving particularly attractive to companies. This event will provide you with an opportunity to meet with and hear from the people who are actually making deals successfully in today’s climate, as they share viable and available methods for accessing capital from investors during this challenging period.
You will learn how to evaluate different alternatives, find new funding sources, and analyze emerging players and their financing models. In addition, with companies often competing for the dollars they badly need, you will discover how to maximize your company’s attractiveness to investors by pursuing development strategies that are in sync with their current investment priorities.
The agenda highlights the latest strategies for success in life science financing. Each session - whether focusing on partnering with the investment arm of a global pharmaceutical or biotech company, working with early or late-stage venture capital investors, or collaborating with a philanthropic organization that is helping to spur research in certain therapeutic areas – will provide you with a sharp analytical focus.
Learn how to carefully tailor terms that impact on corporate control and the interests of early stage investors, and innovative ways to structure alternative financing vehicles. And if future M&A is a possibility for your company, a special focus session will guide you on what you need to do to take into account how the specific terms of any financing that you do today may impact on your ability to make deals. In addition, detailed guidance on specific terms to use in structuring deal terms will be provided in the post-conference Master Class on Drafting Life Science Financial Documents.
About
Dear Distinguished Life Science Leaders:
On behalf of American Conference Institute, we look forward to welcoming you to Financing Solutions and Strategies for Life Sciences in New York this October. With many companies facing a funding crisis, the need for an expert forum on finding solutions to the credit gap and bringing together investors and corporate stakeholders to explore different financial models has never been greater.
With the ways deals are being structured constantly changing, Financing Solutions and Strategies for Life Sciences stands apart as the one event where cutting-edge strategies will be exchanged and potential new relationships will be forged. With distinguished industry speakers and investors coming from notable investment groups including Silicon Valley Bank, OrbiMed, Takeda Research Investment, RBC Capital Markets, Atlas Venture and Paul Capital Healthcare, no other event will arm you both with the knowledge and the networking needed to secure successful financing.
With new stock offerings often no longer a viable option, both companies and venture investors are being forced to adapt. New financial strategies are emerging, and some less dilutive financing models are proving particularly attractive to companies. This event will provide you with an opportunity to meet with and hear from the people who are actually making deals successfully in today’s climate, as they share viable and available methods for accessing capital from investors during this challenging period.
You will learn how to evaluate different alternatives, find new funding sources, and analyze emerging players and their financing models. In addition, with companies often competing for the dollars they badly need, you will discover how to maximize your company’s attractiveness to investors by pursuing development strategies that are in sync with their current investment priorities.
The agenda highlights the latest strategies for success in life science financing. Each session - whether focusing on partnering with the investment arm of a global pharmaceutical or biotech company, working with early or late-stage venture capital investors, or collaborating with a philanthropic organization that is helping to spur research in certain therapeutic areas – will provide you with a sharp analytical focus.
Learn how to carefully tailor terms that impact on corporate control and the interests of early stage investors, and innovative ways to structure alternative financing vehicles. And if future M&A is a possibility for your company, a special focus session will guide you on what you need to do to take into account how the specific terms of any financing that you do today may impact on your ability to make deals. In addition, detailed guidance on specific terms to use in structuring deal terms will be provided in the post-conference Master Class on Drafting Life Science Financial Documents.
Contents & Contributors
Co-Chairs’ Opening Remarks
Samuel P. Wertheimer, Private Equity Partner, OrbiMed Advisors, LLC
Glen Sato, Partner, Cooley Godward Kronish LLP
Making Your Company More Attractive to Investors and Increasing Your Chances for Securing Financing
Dale M. Lombardi, Chief Executive Officer, Secant Pharma, LLC
Early-Stage Financing Case Studies
Mark Kessel, Managing Director, Symphony Capital
Negotiating and Structuring Alternative Forms of Financing that Provide Funds without Giving Up Control of Your Company
John R. Leone, Partner, Paul Capital Healthcare
Forming Successful Alliances with Venture Philanthropy
Timothy Coetzee, Ph.D., President, Fast Forward, LLC
Dr. Gary Olson, CEO, Provid Pharmaceuticals
Leveraging the Investment Resources of Big Pharma and Biotech to Meet Your Life Cycle Needs While Preventing Dilution
Wing Delatorre, M.D., Head of Business Operations, Biogen Idec Innovation Incubator
Using Carve-Out, Spin-Off and Partnering Strategies to Overcome Financial Hurdles
Robin Steele, Senior Vice President and General Counsel, InterMune, Inc.
Faye H. Russell, Partner, Latham & Watkins LLP
Incorporating M&A Considerations into Your Financing Strategy
Glen Sato, Partner, Cooley Godward Kronish LLP
Successful Later-Stage Financing Strategies
Thomas A. Penn, Senior Partner, MVP Captial Partners
Publication Details